Published By : 10 May 2016 | Published By : QYRESEARCH
Breast cancer is the second most common cause for cancer-related deaths across the globe. The rising prevalence of this malignant neoplasm has greatly bolstered the demand for effective and novel therapeutics. The World Cancer Research Fund International states that globally, breast cancer makes up 25 per cent of all the cancer cases in women and a 12 per cent of all new cancer cases, indicating the growing prevalence of breast cancer around the world.
Declining Mortality Rate of Breast Cancer
Over the past few years, the number of women diagnosed with breast cancer has risen exponentially. However, the availability of improved treatment options and the innovation of novel therapeutics have considerably brought down the mortality rate of breast cancer. In fact, the treatment of breast cancer has evolved significantly over the past couple of years, especially owing to the rising use of targeted therapy. The global breast cancer therapeutics market boasts of a wide ranging product landscape and treatment alternatives such as hormonal therapies, chemotherapies, combination therapies, and targeted therapies.
HER2 Inhibitors Strongest Drug Class
The global breast cancer therapeutics market has been segmented based on drug class into anti-metabolites, mitotic inhibitors, HER2 inhibitors, hormone receptors, and aromatase inhibitor hormones. In 2014, HER2 inhibitors emerged as the strongest segment in the market. HER2 receptor type cancer is the most invasive breast cancer but is not difficult to detect and treat owing to the recent advances in companion testing and targeted therapies. As a result, the drugs used in the treatment of this kind of breast cancer dominate the overall breast cancer therapeutics market. The growing demand for Herceptin, in addition to Perjeta and Kadcyla has added to the rapid expansion of the global market for breast cancer therapeutics.
Reports indicate that the worldwide market is majorly boosted by the growing success of targeted therapies as well as the rapid approval of drugs and therapies under programs launched by the United States Food and Drugs Administration.